October 21st 2024
Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the agent in consultation with the FDA.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Determining a Role for Neoadjuvant/Adjuvant Therapy in RCC
May 22nd 2017Much research has been done to define the role of neoadjuvant and adjuvant therapies in metastatic renal cell carcinoma patients who have diseease recurrence after surgical resection, but the standard of care has not significantly changed.
Read More
Role of PARP Inhibitors Clarified in Prostate Cancer
May 22nd 2017Our understanding of the genomic landscape of metastatic castration-resistant prostate cancer has been rapidly progressing, with new clinical data emerging to clarify and, in many cases, support the use of PARP inhibitors in the treatment of these patients.
Read More
Results for Pembrolizumab as a First-Line Therapy for Advanced Urothelial Carcinoma
May 22nd 2017Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discussed results of the KEYNOTE-052 study of pembrolizumab as a first-line therapy for patients with cisplatin-ineligible advanced urothelial cancer.
Watch
Affordable Care Act Associated With Shift to Earlier-Stage Cancer Diagnosis
May 18th 2017More Stage I cancers were diagnosed after the passage of the Affordable Care Act within 5 screenable disease types (colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer) than were diagnosed before ACA implementation.
Read More
Burnout Remains an Important Issue in Urology, Despite Decreased Occurrence
May 16th 2017Based on results from Maslach Burnout Inventory (MBI) questions included as part of the 2016 American Urological Association (AUA) Census, burnout rates among urologists are lower than previously reported, but the issue still remains important.
Read More
AR-V7 Associated With Poorer Outcomes in Castration-Resistant Prostate Cancer
April 21st 2017The presence of androgen receptor splice variant-7 mRNA in circulating tumor cells was associated with poorer outcomes for men with castration-resistant prostate cancer assigned to novel hormonal therapies.
Read More
Active Surveillance May Provide QoL Benefits for Low-Risk Prostate Cancer
March 29th 2017Daniel A. Barocas, MD, discusses a study that compared differences in quality of life among patients who have undergone radical prostatectomy, external beam radiotherapy, brachytherapy or active surveillance for low-risk prostate cancer.
Read More
Next Few Years Will Bring Immunotherapy to the Forefront of Therapy for Urothelial Carcinoma
March 28th 2017Evan Y. Yu, MD, discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space, and the possibilities for the future treatment landscape.
Read More
Expert Highlights Data Supporting Moderate Hypofractionation as New Standard in Prostate Cancer
March 23rd 2017James B. Yu, MD, discusses the current data in support of using moderate hypofractionation in prostate cancer, as well as recent data showing how genomic testing can help with treatment decision making postoperatively.
Read More
Apolo Discusses Promising Immunotherapy Combos in Bladder Cancer
March 6th 2017Andrea Apolo, MD, discusses promising early data demonstrating the activity and safety of cabozantinib and nivolumab, with or without ipilimumab, in bladder cancer and other advanced genitourinary cancers.<br />
Read More
Study Results Support Novel Focal Therapy for Low-Risk Prostate Cancer
February 17th 2017A novel tissue-preserving treatment, padeliporfin vascular-targeted photodynamic therapy, may offer men with low-risk prostate cancer a safe and effective alternative to either active surveillance or radical therapy.
Read More
New Marker Could Help Detect Need for More Aggressive Prostate Cancer Treatment
January 27th 2017A prostate-specific antigen nadir greater than 0.5 ng/mL following radiation and androgen deprivation therapy seems to identify men prior to PSA failure who are at high-risk for death, and would thus require more aggressive treatment for their prostate cancer.
Read More
Sharp Decline Seen in Prostate Cancer Treatment Rates
January 27th 2017Tudor Borza, MD, discusses the major findings of his study that found a sharp decline in the overall rate of men receiving treatment for prostate cancer and his stance on the importance of prostate cancer screening and treatment.
Read More